Age plays a key role in evaluating the right therapy as it has emerged that women between 40 and 50 years old who suffer from hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer, a high clinical risk, and low genomic risk had a greater benefit from chemotherapy than those aged >50 years.
In the MINDACT trial, the utility of the 70-gene signature commercial diagnostic test MammaPrint was compared with common clinical-pathological criteria to select breast cancer patients with 0 to 3 positive nodes for adjuvant chemotherapy. An unplanned analysis of MINDACT was performed, aiming to determine whether the addition of chemotherapy had an age-dependent impact on distant metastasis-free survival (DMFS) among certain breast cancer patients . The reason for this analysis were recent findings of the TAILORx trial, which demonstrated that patients aged <50 years had an estimated chemotherapy benefit in reducing dista...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Letter from the Editor Next Article
Residual cancer burden is a predictor for all-type breast cancer patients »